Pfizer
Talazoparib Plus Enzalutamide for HRR Gene-Altered mCRPC Receives FDA Approval
Source – FDA On June 20, 2023, the combination of talazoparib (Talzenna) and enzalutamide (Xtandi) has been approved by the ...
Pfizer Joins Prostate Cancer PARP Showdown: A Three-Way Battle for Breakthrough Treatment
Pfizer expects that the FDA’s approval of Talzenna, a PARP inhibitor, for castration-resistant prostate cancer (CRPC) would enable it to ...
CDC advisory group reviews GSK and Pfizer RSV vaccinations
Source – Fierce Pharma On June 21, 2023, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease ...
Comprehensive Guide to mRNA Vaccines: Advancements in COVID-19 Immunization
Introduction At our organization, we are dedicated to providing valuable information on the latest advancements in COVID-19 vaccines. In this ...
LIPITOR: The Unprecedented Success Story of the Most Profitable Drug in Pharmaceutical History
In the pharmaceutical landscape, certain drugs have achieved unparalleled success in terms of profitability, with LIPITOR standing out as the ...
Pfizer updates papers for its $43 billion acquisition of Seagen as the FTC keeps a watch on biopharma M&A deals
Source: Pfizer A month later, Pfizer withdrew its notice for its proposed $43 billion acquisition of cancer medication expert Seagen ...
In Germany, a COVID-19 vaccine damage claim will be defended by BioNTech
Source- BioNTech The COVID-19 vaccine partner of Pfizer, BioNTech, is going to court in its native Germany to defend itself ...
Samsung Biologics Secures $411 Million Long-Term Deal with Pfizer for Biosimilar Production
South Korea’s Samsung Biologics has recently entered into another significant manufacturing agreement, this time with Pfizer, worth $411 million. The ...
Pfizer’s RSV Vaccine ABRYSVO: A Breakthrough for the Industry and RSV Prevention
Pfizer’s RSV Vaccine: In a groundbreaking development, Pfizer’s FDA approval for its RSV vaccine, ABRYSVO, has not only positioned the ...
Pfizer’s Phase III Trials Bring Hope for Multidrug-Resistant Infections with Limited Treatment Options
On June 1, 2023, Pfizer announced encouraging outcomes from its Phase III program that involved the REVISIT and ASSEMBLE trials. ...
